Free Trial

Marinus Pharmaceuticals (MRNS) News Today

$1.38
+0.08 (+6.15%)
(As of 05/24/2024 ET)
Oppenheimer Reaffirms Their Hold Rating on Marinus (MRNS)
Marinus Pharmaceuticals: Q1 Earnings Snapshot
Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Lowered to $11.00 at HC Wainwright
HC Wainwright reduced their target price on shares of Marinus Pharmaceuticals from $27.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday.
Marinus Pharmaceuticals (MRNS) Set to Announce Quarterly Earnings on Wednesday
Marinus Pharmaceuticals (NASDAQ:MRNS) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.
abrdn plc Acquires New Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
abrdn plc acquired a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 552,572 shares of the biopharmaceutical company's stock, valued at approximately $6,006,000. abrdn plc
Marinus Pharmaceuticals Inc (MRNS)
Truist Financial Trims Marinus Pharmaceuticals (NASDAQ:MRNS) Target Price to $10.00
Truist Financial reduced their price target on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday.
Cantor Fitzgerald Comments on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued on Tuesday, April 16th. Cantor Fitzgerald analyst C. Duncan now forecasts that the
Marinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Neutral" at Robert W. Baird
Robert W. Baird cut Marinus Pharmaceuticals from an "outperform" rating to a "neutral" rating and lowered their target price for the company from $20.00 to $2.00 in a research report on Tuesday.
Marinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Sector Perform" at Royal Bank of Canada
Royal Bank of Canada downgraded Marinus Pharmaceuticals from an "outperform" rating to a "sector perform" rating and dropped their target price for the company from $24.00 to $3.00 in a report on Monday.
Why Are Stocks Up Today?
Marinus Pharmaceuticals' (MRNS) Overweight Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reaffirmed an "overweight" rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Rating of "Moderate Buy" by Brokerages
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given
Marinus Pharmaceuticals Inc MRNS
Assenagon Asset Management S.A. Reduces Stock Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)
Assenagon Asset Management S.A. lessened its stake in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) by 47.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 271,157 shares of the bi
Leerink Partnrs Weighs in on Marinus Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2025 EPS estimates for Marinus Pharmaceuticals in a note issued to investors on Sunday, March 24th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company
HC Wainwright Reiterates "Buy" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)
HC Wainwright reissued a "buy" rating and issued a $27.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday.
MRNS Jul 2024 16.000 call
MRNS Mar 2024 7.000 put
Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Up 8.5%
Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Price Up 8.5%
Leerink Partnrs Weighs in on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Marinus Pharmaceuticals in a report released on Tuesday, March 5th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmac
Get Marinus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Claim Your Complimentary Bitcoin Reward (Ad)

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

MRNS Media Mentions By Week

MRNS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MRNS
News Sentiment

0.38

0.77

Average
Medical
News Sentiment

MRNS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MRNS Articles
This Week

2

2

MRNS Articles
Average Week

Get Marinus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:MRNS) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners